Saccharomyces cerevisiae UFMG A-1009

Saccharomyces cerevisiae UFMG A-1009 is a probiotic yeast strain whose beta-glucans and cell wall components modulate immune responses by interacting with pattern recognition receptors such as Dectin-1 and TLRs. Preclinical research indicates it suppresses Th2-driven inflammation in asthma models and attenuates intestinal inflammation in colitis models by downregulating pro-inflammatory cytokines.

Origin & History

Saccharomyces cerevisiae UFMG A-1009 is a specific strain of budding yeast from the UFMG series, originating from Brazilian research collections (likely Universidade Federal de Minas Gerais). As a live yeast cell probiotic rather than an extract, it belongs to the fungal kingdom Ascomycota and is studied for potential therapeutic applications.

Historical & Cultural Context

No historical or traditional medicine use identified for UFMG A-1009/A-905 strains. These are modern research strains without documented links to traditional healing systems like Ayurveda or TCM.

Health Benefits

• May reduce airway inflammation in asthma models (preclinical evidence only - reduced bronchial hyperresponsiveness and Th2 cytokines in mice)
• Potentially improves inflammatory bowel conditions (preclinical evidence only - improved clinical scores and reduced inflammation in DSS-induced colitis mice, PMID: 26322540)
• Could attenuate food allergy reactions (preclinical evidence only - reduced tissue injury and myeloperoxidase activity in ovalbumin-challenged mice, PMID: 32264688)
• May protect against chemotherapy-induced intestinal damage (preclinical evidence only - reduced irinotecan-induced mucositis in mice, PMID: 27133563)
• Possible immunomodulatory effects via gut-lung axis (preclinical evidence only - increased regulatory T cells and dendritic cells in murine models)

How It Works

Saccharomyces cerevisiae UFMG A-1009 cell wall beta-1,3/1,6-glucans and mannoproteins bind Dectin-1 and Toll-like receptor 2 (TLR2) on dendritic cells and macrophages, promoting regulatory immune signaling that suppresses Th2 cytokine production including IL-4, IL-5, and IL-13. In gut models, this interaction activates NF-κB regulatory pathways that reduce secretion of TNF-α, IL-6, and IL-1β, helping restore intestinal epithelial barrier integrity. The strain may also shift gut microbiota composition toward beneficial taxa, indirectly dampening inflammatory cascades through short-chain fatty acid production.

Scientific Research

No human clinical trials, RCTs, or meta-analyses exist for S. cerevisiae UFMG A-1009 or the closely related UFMG A-905 strain. All available evidence comes from preclinical murine models studying asthma (PMID: 28166610), ulcerative colitis (PMID: 26322540), food allergy (PMID: 32264688), and chemotherapy-induced mucositis (PMID: 27133563).

Clinical Summary

Evidence for Saccharomyces cerevisiae UFMG A-1009 is currently limited to preclinical animal studies; no peer-reviewed human clinical trials have been published as of 2024. In murine asthma models (ovalbumin-sensitized mice), oral administration reduced bronchial hyperresponsiveness and significantly lowered BAL fluid levels of IL-4, IL-5, and IL-13 compared to controls. In dextran sodium sulfate (DSS)-induced colitis mouse models, supplementation improved disease activity index scores, reduced colon shortening, and decreased mucosal TNF-α and IL-6 expression. These results are hypothesis-generating and cannot be extrapolated to humans without controlled clinical trials.

Nutritional Profile

Saccharomyces cerevisiae UFMG A-1009 is a probiotic yeast strain with a nutritional composition broadly consistent with Saccharomyces cerevisiae species, though strain-specific quantitative data is limited. As a yeast cell, its biomass is composed of approximately 45-60% protein (dry weight) containing all essential amino acids, with lysine and threonine as notable contributors. Carbohydrate content ranges from 30-45% dry weight, dominated by cell wall polysaccharides including beta-1,3/1,6-glucans (estimated 25-35% of dry cell wall mass) and chitin (1-3%), which are key bioactive immunomodulatory compounds. Mannan/mannoproteins constitute an additional 20-30% of cell wall content and contribute to gut immune interactions. Lipid content is relatively low at 4-7% dry weight, primarily composed of phospholipids, ergosterol (a precursor to vitamin D2), and unsaturated fatty acids. B-vitamin content is notable: thiamine (B1) ~0.5-1.5 mg/100g dry weight, riboflavin (B2) ~3-5 mg/100g, niacin (B3) ~35-60 mg/100g, pantothenic acid (B5) ~10-20 mg/100g, pyridoxine (B6) ~2-4 mg/100g, and folate ~2-3 mg/100g. Minerals present include zinc (~7-10 mg/100g), selenium (variable, strain/medium dependent), chromium, and iron. Nucleotides (RNA-derived) may comprise 6-12% dry weight. Bioavailability of nutrients from intact yeast cells is moderate due to the cell wall barrier, but beta-glucans and mannoproteins remain bioactive in particulate form and interact directly with intestinal immune receptors (Dectin-1, TLR2). Strain-specific compositional data for UFMG A-1009 beyond immunological characterization has not been published in peer-reviewed literature as of the available evidence base.

Preparation & Dosage

No human dosage data available. Preclinical studies used 10^7 to 10^9 CFU/mL via oral gavage in mice, with 10^9 CFU/mL showing optimal effects. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic strains, prebiotics, omega-3 fatty acids, quercetin, vitamin D

Safety & Interactions

Saccharomyces cerevisiae strains are generally recognized as safe (GRAS) for healthy adults, but this specific UFMG A-1009 strain lacks formal human safety data from clinical trials. Individuals with Saccharomyces-related fungal sensitivities, compromised immune systems, or central venous catheters should avoid probiotic yeast supplementation due to rare but reported risk of fungemia. No drug interaction data exists specifically for UFMG A-1009, though probiotic yeasts theoretically may reduce efficacy of antifungal medications such as fluconazole if taken concomitantly. Pregnancy and pediatric safety have not been evaluated and use in these populations is not recommended without medical supervision.